2013
Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer
YING L, SU D, ZHU J, MA S, KATSAROS D, YU H. Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncology Letters 2013, 5: 1315-1320. PMID: 23599786, PMCID: PMC3629093, DOI: 10.3892/ol.2013.1144.Peer-Reviewed Original ResearchOvarian cancerSingle nucleotide polymorphismsPlatinum-based chemotherapyEpithelial ovarian cancerFresh tumor samplesPhenotype of patientsCytoreductive surgeryClinical factorsClinical outcomesPatientsStathmin geneCancerTumor samplesHuman cancersSurgeryDirect sequencingTotalLinkage disequilibrium blockAssociationPresent studyStathminNucleotide polymorphismsOutcomesDisequilibrium blockDNA samples
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patients